demonstrated that S100A9 levels in rat liver and serum were consistent with hepatic mRNA levels, suggesting its potential as a biomarker for predicting NAFLD progression and distinguishing between phenotypes (38). This evidence concerns the gene S100A9 and metabolic dysfunction-associated steatotic liver disease.